NCT07458542Completed
Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to assess real-world effectiveness and safety of oral azacitidine in adults diagnosed with acute myeloid leukemia (AML) in Hong Kong
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 44 (actual)
- First submitted
- 25 Feb 2026
- Start date
- 9 Dec 2025
- Primary completion date
- 9 Jan 2026
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07458542
What you commit to
- Study type: Observational
- Participants enrolled: 44
- From 9 Dec 2025 to the primary completion date, 9 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Evidence of relapse prior to oral azacitidine initiation recorded in electronic health record (EHR).
Who the study is looking for
- Documented diagnosis of Acute Myeloid Leukemia (AML).
- Achieved first complete response (CR) or complete response with incomplete blood recovery (CRi) following intensive induction chemotherapy.
- Not able or unwilling to undergo Hematopoietic Stem Cell Transplantation (HSCT).
- Received oral azacitidine as maintenance therapy after first CR or CRi following intensive induction chemotherapy in real-world settings (Note: CR/CRi status at oral azacitidine treatment initiation is left to the judgment of the local clinicians depending on the treatment response and the condition of the patient in routine clinical practices).
- Age ≥ 18 years at the index date (oral azacitidine initiation date).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.